Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Is Gilead Sciences Stock Still a Buy After Soaring in 2022?
05:52am, Thursday, 08'th Dec 2022
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
Gilead Sciences, Inc. (GILD) Presents at NASDAQ 47th Investor Conference (Transcript)
01:40pm, Wednesday, 07'th Dec 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) NASDAQ 47th Investor Conference December 7, 2022 8:00 AM ET Company Participants Dan O'Day - Chairman and CEO Conference Call Participants Matthew Harrison - Morga
5 Dividend Stocks to Allay Fears of a More-Aggressive Fed
09:47am, Tuesday, 06'th Dec 2022
As U.S. stocks stumble on concerns of further rate hikes, investing in dividend players like Exxon Mobil (XOM), Gilead Sciences (GILD) and Conagra Brands (CAG) for a steady stream of income seems prud
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
12:02pm, Monday, 05'th Dec 2022
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
11:17am, Monday, 05'th Dec 2022
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
The Top Healthcare Stocks to Buy With $100
09:05am, Thursday, 01'st Dec 2022
Triple-digit growth and innovation go hand-in-hand with these companies.
Gilead Sciences, Inc. (GILD) Management presents at Piper Sandler Healthcare Conference (Transcript)
02:45pm, Wednesday, 30'th Nov 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) Piper Sandler Healthcare Conference November 30, 2022 11:30 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Do Kim -
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
09:02am, Wednesday, 30'th Nov 2022
Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.
2 Reasons This Stock Could Outperform in 2023
08:37am, Wednesday, 30'th Nov 2022
It would be a continuation of this year's showing.
These 3 Stocks Are Rallying While the Rest of the Market Plunges
05:12am, Wednesday, 30'th Nov 2022
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.
Gilead Sciences, Inc. (GILD) 2022 5th Annual Evercore ISI HealthCONx Conference(Transcript)
08:58pm, Tuesday, 29'th Nov 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) 2022 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 1:00 PM ET Company Participants Andrew Dickinson - Executive Vice President & Chief Finan
These Are the Five Best and Worst Performing Healthcare Stocks in October 2022
08:02pm, Monday, 28'th Nov 2022
The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
12:27pm, Monday, 28'th Nov 2022
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. The post Gilead's Cancer Program Notches Another Wi
Pick These 4 Stocks With Exciting Interest Coverage Ratio
09:02am, Friday, 25'th Nov 2022
A company capable of generating earnings well above its interest expense can withstand financial hardship. General Mills (GIS), Texas Roadhouse (TXRH), O'Reilly Automotive (ORLY) and Gilead Sciences (
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
10:32am, Wednesday, 23'rd Nov 2022
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
